PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 15, 2026Antioxidants0 citationsOpen Access

SUMOylation Inhibitor TAK-981 Mitigates Preeclampsia Features Linked to Glucocorticoids

SUMOylation Inhibitor TAK-981 Alleviates Hallmark Features of Preeclampsia Related to High Glucocorticoid Exposure by Inhibiting Placental Oxidative Stress in Rats

View Full Paper
Ask AI
Bookmark
Share

Authors

SXS J XiaoYZY. ZhangZTZhen Tang

Discussion

Loading...

Member takes

Overview

Animal and cell models demonstrate TAK-981 improves preeclampsia outcomes, suggesting a new treatment approach.

Key Points

  • The aim is to explore the role of SUMOylation in preeclampsia and its mechanisms under glucocorticoid exposure.
  • Established a rat preeclampsia model using dexamethasone (DEX) treatment.
  • Utilized HTR8 and BeWo trophoblast cell models.
  • Conducted placental RNA-seq and Western blot analyses to assess SUMOylation levels.
  • Administered SUMOylation inhibitor TAK-981 to evaluate its effects on PE features.
  • TAK-981 reduced the hallmark features of preeclampsia, including high blood pressure and renal injury.
  • Treatment improved fetal weight and placental blood flow in the DEX-treated rat model.
  • In cell models, TAK-981 reversed DEX-induced dysfunction in migration, invasion, and syncytialization.
  • GEO database analysis showed increased SUMOylation in human placentas with preeclampsia.

Cite This Study

Xiao et al. (2026) studied this question.

synapsesocial.com/papers/69df2ae6e4eeef8a2a6afda0https://doi.org/10.3390/antiox15040478
View Full Paper
Ask AI
Bookmark
Share